Weight-bearing of Surgically Treated Acetabular Fractures.

Sponsor
Hospital District of Helsinki and Uusimaa (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04724811
Collaborator
(none)
50
1
2
81.9
0.6

Study Details

Study Description

Brief Summary

The purpose of this study is to determine whether patients with operatively treated acetabular fractures benefit from early weight-bearing as tolerated. The study compares two groups ( n = 25 each), which are randomised into either weight-bearing as tolerated or touch-down weight-bearing for 6-8 weeks postoperatively.

Both study groups are stratified according to

  • Type of fracture (anterior approach vs anterior + additional posterior approach)

  • Dislocated dome vs non-dislocated/ non existing separate dome fragment

Patients, who are eligible to participate in the trial but choose not to participate in randomisation are asked to enrol in a prospective cohort follow-up cohort. This is to examine a potential participation bias in the RCT groups. These patients will not be counted into the target amount of 50 RCT patients.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Open reduction and internal fixation (ORIF)
N/A

Detailed Description

For the past 20 years, the established treatment of dislocated acetabular fractures has been surgical reduction and stable osteosynthesis. Good long-term results have been reported in these patients. At present, the mobilisation of these patients after surgery is generally restricted for several weeks ranging from 6-12 weeks touch-down- or non-weight-bearing with no uniform protocol. However there is no scientific evidence for limiting post operative weight-bearing. Accordingly the need of studies on weight-bearing surrounding periarticular fractures has been advocated.

Acetabular fractures in the elderly population are becoming more common and pose significant challenges for treatment including postoperative rehabilitation. Our aim is to investigate if patients benefit of a more liberal weight-bearing regime postoperatively. The primary outcome is measured at 1 year, secondary outcomes are followed up to 10 years postoperatively

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Prospective randomised non-inferiority studyProspective randomised non-inferiority study
Masking:
Double (Care Provider, Investigator)
Masking Description:
The surgeon is masked The investigator is masked
Primary Purpose:
Treatment
Official Title:
Weight-bearing of Surgically Treated Acetabular Fractures. A Randomised Controlled Trial
Anticipated Study Start Date :
Feb 1, 2021
Anticipated Primary Completion Date :
Dec 1, 2026
Anticipated Study Completion Date :
Dec 1, 2027

Arms and Interventions

Arm Intervention/Treatment
Experimental: Weight-bearing as tolerated

Patients are instructed to mobilise the hip and weight-bear as tolerated

Procedure: Open reduction and internal fixation (ORIF)
Approaches used: Intrapelvic approach +/- iliac window Kocher-Langenbeck approach

Active Comparator: Touch-down weight-bearing

Patients are instructed to mobilise the hip. Touch-down weight-bearing for 6-8 weeks

Procedure: Open reduction and internal fixation (ORIF)
Approaches used: Intrapelvic approach +/- iliac window Kocher-Langenbeck approach

Outcome Measures

Primary Outcome Measures

  1. mHHS [1 year]

    Modified Harris Hip Score

  2. NRS [1 year]

    Pain during gate, Numerical Rating Scale

Secondary Outcome Measures

  1. mHHS [0 weeks, 6 weeks, 12 weeks, 6 months, 2 years, 5 years, 10 years]

    Modified Harris Hip Score

  2. NRS [0 weeks, 6 weeks, 12 weeks, 6 months, 1 year, 2 years, 5 years, 10 years]

    Pain at rest and during gate, Numerical Rating Scale

  3. WOMAC [0 weeks, 1 year, 2 years, 5 years, 10 years]

    Western Ontario and McMaster Universities Osteoarthritis Index

  4. RAND36 [0 weeks, 1 Year, 2 years, 5 years, 10 years]

    Patient reported quality of life

Other Outcome Measures

  1. Complications [At any point of time during treatment]

    Intra-operative blood loss, nerve damage, loss of reduction, protrusion, re-operation, infection, VTE, AVN, heterotypic ossification, death

  2. Total hip replacement [During 10 years postoperatively]

    Conversion to total hip replacement

  3. Reduction of the articular surface after surgery [Postoperatively]

    The reduction is assessed with a postoperative CT scan

Eligibility Criteria

Criteria

Ages Eligible for Study:
60 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Unilateral dislocated acetabulum fracture (displacement of over 2mm in preoperative CT scan)

  • The osteosynthesis is performed during 21 days after initial trauma

  • The patient is willing to participate in the follow-up

Exclusion Criteria:
  • Unwillingness to participate in randomisation

  • Bilateral fracture

  • Letournel & Judet type Both column or Posterior column and wall fractures

  • Any other injury that prevents the patient from partial weight bearing

  • Open fracture of the acetabulum

  • Pathologic fracture (fragility fractures are not an exclusion criteria)

  • Prior functional disability in the pelvis or lower extremity

  • Non-Compliance due to dementia or other mental disability

  • Prior daily pain medication due to hip-pain

  • Unwillingness to accept one of the two mobilisation protocols

  • Prior hip replacement on injured side

  • BMI > 40

Contacts and Locations

Locations

Site City State Country Postal Code
1 Helsinki University Hospital Helsinki Uusimaa Finland 00029 HUS

Sponsors and Collaborators

  • Hospital District of Helsinki and Uusimaa

Investigators

  • Study Chair: Jan Lindahl, MD, PhD, Helsinki University Central Hospital
  • Principal Investigator: Kristian Seppänen, MD, Helsinki University Central Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Kristian Seppänen, Principal Investigator, Hospital District of Helsinki and Uusimaa
ClinicalTrials.gov Identifier:
NCT04724811
Other Study ID Numbers:
  • HUS/234/2020
First Posted:
Jan 26, 2021
Last Update Posted:
Jan 26, 2021
Last Verified:
Jan 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Kristian Seppänen, Principal Investigator, Hospital District of Helsinki and Uusimaa
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 26, 2021